We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
LGC Clinical Diagnostics

Download Mobile App




AI Holography System Accurately Checks Quality of Red Blood Cells

By LabMedica International staff writers
Posted on 15 Aug 2022
Print article
Image: AI holography system checks blood quality without injections (Photo courtesy of Pexels)
Image: AI holography system checks blood quality without injections (Photo courtesy of Pexels)

Red blood cells are a major component of blood that carries oxygen. Red blood cells collected through blood donation are stored for a certain period of time until they are used for transfusion when needed. This process is necessary because unhealthy red blood cells do not function properly and may lead to fatal side effects such as acute lung damage. Conventionally, image-based red blood cell analysis technology is used, which is an invasive method that destroys the three-dimensional structure of red blood cells as red blood cells are observed after staining. In addition, there are technical limitations in rapidly analyzing state changes such as three-dimensional shape, density change, and motility characteristics of red blood cells. To overcome this problem, a research team has developed an AI holography system that automatically extracts important information and inspects the quality of red blood cells. The new system is expected to become a key technology for enabling cleaner and healthier red blood cell injections to patients through accurate quality inspection of red blood cells stored for a certain period of time for blood transfusion.

Scientists at Daegu Gyeongbuk Institute of Science and Technology (DGIST, Daegu, Korea) had earlier developed 'holography-based red blood cell division and classification technology.' However, this requires a number of pre-processing algorithms before analysis, which takes a long time, and involves difficulties in performing accurate analysis and classification. In response, the team successfully developed an AI holography system that automatically inspects the quality of red blood cells stored for a certain time by combining the 3D structure image data of red blood cells obtained with holography technology and generative adversarial neural network technology.

If the developed technology is used, it will be possible to automatically extract important values ​​of judgment for red blood cells by applying the automatic red blood cell 3D structural image analysis algorithm and also check its quality. In particular, it is possible to test the quality of red blood cells precisely and simply as there is no need for invasive methods or pre-treatment procedures required by existing technologies. It is expected to be used as a core technology to help minimize the side effects of transfusion by injecting clean and healthy red blood cells to patients needing blood transfusions.

“The technology developed through this research is the source technology that can automatically analyze how red blood cells, stored for transfusion, change their three-dimensional shape depending on the storage period and determine whether stored red blood cells are healthy red blood cells that can be transfused,” said Professor Moon In-kyu of the Department of Robotics and Mechatronics Engineering at DGIST who led the research team. “It is expected that it will help minimize the occurrence of side effects after transfusion in the future as it can check the state of stored red blood cells more minutely and test whether the red blood cells are safe for the patient before transfusion.”

Related Links:
DGIST 

Gold Member
Antipsychotic TDM Assays
Saladax Antipsychotic Assays
Verification Panels for Assay Development & QC
Seroconversion Panels
New
Cytomegalovirus Test
NovaLisa Cytomegalovirus (CMV) IgG Test
New
Fixed Speed Tube Rocker
GTR-FS

Print article

Channels

Clinical Chemistry

view channel
Image: QIP-MS could predict and detect myeloma relapse earlier compared to currently used techniques (Photo courtesy of Adobe Stock)

Mass Spectrometry-Based Monitoring Technique to Predict and Identify Early Myeloma Relapse

Myeloma, a type of cancer that affects the bone marrow, is currently incurable, though many patients can live for over 10 years after diagnosis. However, around 1 in 5 individuals with myeloma have a high-risk... Read more

Immunology

view channel
Image: The cancer stem cell test can accurately choose more effective treatments (Photo courtesy of University of Cincinnati)

Stem Cell Test Predicts Treatment Outcome for Patients with Platinum-Resistant Ovarian Cancer

Epithelial ovarian cancer frequently responds to chemotherapy initially, but eventually, the tumor develops resistance to the therapy, leading to regrowth. This resistance is partially due to the activation... Read more

Technology

view channel
Image: Ziyang Wang and Shengxi Huang have developed a tool that enables precise insights into viral proteins and brain disease markers (Photo courtesy of Jeff Fitlow/Rice University)

Light Signature Algorithm to Enable Faster and More Precise Medical Diagnoses

Every material or molecule interacts with light in a unique way, creating a distinct pattern, much like a fingerprint. Optical spectroscopy, which involves shining a laser on a material and observing how... Read more

Industry

view channel
Image: The collaboration aims to leverage Oxford Nanopore\'s sequencing platform and Cepheid\'s GeneXpert system to advance the field of sequencing for infectious diseases (Photo courtesy of Cepheid)

Cepheid and Oxford Nanopore Technologies Partner on Advancing Automated Sequencing-Based Solutions

Cepheid (Sunnyvale, CA, USA), a leading molecular diagnostics company, and Oxford Nanopore Technologies (Oxford, UK), the company behind a new generation of sequencing-based molecular analysis technologies,... Read more
Copyright © 2000-2025 Globetech Media. All rights reserved.